NCT07191717View on ClinicalTrials.gov

Imlunestrant and Abemaciclib for the Treatment of Estrogen Receptor Positive Breast Cancer in Patients With Minimal Residual Disease, MIRI Trial

PHASE2Not yet recruitingINTERVENTIONAL
Enrollment

42

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

September 30, 2030

Study Completion Date

September 30, 2031

Conditions
Anatomic Stage I Breast Cancer AJCC v8Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8Invasive Breast CarcinomaLocalized Estrogen Receptor-Positive Breast CarcinomaLocalized Human Epidermal Growth Factor Receptor (HER2)-Negative Breast Carcinoma
Interventions
DRUG

Abemaciclib

Given PO

PROCEDURE

Biospecimen Collection

Undergo blood sample collection

DRUG

Imlunestrant

Given PO

OTHER

Questionnaire Administration

Ancillary studies

PROCEDURE

Radiologic Imaging Procedure

Undergo radiologic scans

Trial Locations (1)

90095

UCLA / Jonsson Comprehensive Cancer Center, Los Angeles

All Listed Sponsors
lead

Jonsson Comprehensive Cancer Center

OTHER